Lab discovery could allow for heparin produced by cell lines

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/4ndrei)
(Image: Getty/4ndrei)

Related tags: Heparin, Cell lines

Researchers from UC San Diego identify a critical gene in the heparin biosynthesis process, which could pave the way for future industrial production.

Heparin is a widely-used anti-coagulant and is currently produced through extraction from pig intestines – though this means that production can be impacted by external factors, such as the spread of swine flu.

Last year​, the US Food and Drug Administration had to issue a statement that supplies of heparin were not impacted by African swine flu in China, though earlier this year The Lancet published​ an article suggesting that there were still concerns over supply.

As a result, researchers from the University of California San Diego stated that there is a need to “develop sustainable recombinant production,”​ further suggesting that they had made a ‘key discovery’ in this direction.

In particular, the researcher discovered that the gene ZNF263 is an active repressor of heparin biosynthesis throughout most cell types, while mast cells, which produce heparin, were enabled to produce the compound when the gene was suppressed.

This was managed by utilizing bioinformatic software to scan the genes encoding enzymes related to heparin production and then look for sequence elements that could be binding sites for transcription factors.

Due to this finding, the researchers suggested that cell lines currently used by industry, such as CHO cell lines, could be genetically modified to produce heparin in an industrial setting.

Further than this, researchers involved in the project stated that additional related gene regulators involved in heparin production had also been discovered and would form the basis of future studies.

Related topics: Upstream Processing, Cell lines

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us


View more